ArticleJAMA oncology2018
Incidence of Diabetes After Cancer Development: A Korean National Cohort Study.
Article in JAMA oncology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 106 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
106 citing papers in PubMed, 5 syntheses or guidelines pooled it, 156 citations in OpenAlex.
- Revisiting insulin resistance in human cancer cachexia - a systematic review and meta-analysis.Acta oncologica (Stockholm, Sweden) · 2025Pooled it
- Vaccination of people with solid tumors and diabetes: existing evidence and recommendations. A position statement from a multidisciplinary panel of scientific societies.Journal of endocrinological investigation · 2025Guideline
- Combined Aerobic and Resistance Training Improves Body Composition, Alters Cardiometabolic Risk, and Ameliorates Cancer-Related Indicators in Breast Cancer Patients and Survivors with Overweight/Obesity: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.Journal of sports science & medicine · 2024Pooled it
- Breast cancer and incidence of type 2 diabetes mellitus: a systematic review and meta-analysis.Breast cancer research and treatment · 2023Pooled it
- New onset of type 2 diabetes as a complication after cancer diagnosis: A systematic review.Cancer medicine · 2021Pooled it
- A nurse-led intervention in patients with newly diagnosed cancer and Type 2 diabetes: A pilot randomized controlled trial feasibility study.Cancer medicine · 2023Trial
- A randomized trial of exercise and diet on body composition in survivors of breast cancer with overweight or obesity.Breast cancer research and treatment · 2021Trial
- Systemic health impact of cancer-associated extracellular vesicles and particles.Nature reviews. Cancer · 2026Review
- Electronic cigarette use after smoking cessation and lung cancer risk.Nature medicine · 2026Article
- Identifying PLAU as a shared pathogenic gene in type 2 diabetes and bladder urothelial carcinoma through integrated transcriptomic analysis and machine learning for diagnostic and therapeutic value.Clinical and experimental medicine · 2026Article
- Late effects among colorectal cancer survivors ≥5 years after diagnosis-a systematic scoping review.JNCI cancer spectrum · 2026Article
- A comprehensive nationwide registry study of noncommunicable disease comorbidities and death in cancer patients in Norway-the NCDNOR project.Scientific reports · 2026Article
- New-onset prediabetes/diabetes worsens overall survival in patients with cancer: A real-world retrospective cohort study.Diabetes, obesity & metabolism · 2026Article
- Integrated Genomic-Metabolomic Analysis for Tri-Categorical Classification of Type 2 Diabetes Status in the Korean Ansan-Ansung Cohort.International journal of molecular sciences · 2025Article
- Neighborhood factors associated with late effects among survivors of adolescent and young adult cancer.Journal of cancer survivorship : research and practice · 2025Article
- Changes in physical activity and diabetes risk after cancer diagnosis: a nationwide cohort study.Journal of cancer survivorship : research and practice · 2025Article
- Association of Pre- and Postdiagnosis Physical Activity, Promotion and Maintenance With Lung Cancer Survival: A Nationwide Cohort Study.Journal of cachexia, sarcopenia and muscle · 2025Article
- Risk classification for non-cancer death in middle-aged cancer patients.Journal of advanced research · 2025Article
- Insulin resistance and cancer: molecular links and clinical perspectives.Molecular and cellular biochemistry · 2025Review
- Increased risk of lung cancer in individuals with preserved ratio impaired spirometry: a nationwide cohort study.Scientific reports · 2025Article
46 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
18 authors at 5 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Importance: Diabetes is an established risk factor for developing cancer. A limited body of evidence also suggests that cancer can increase the risk of developing new cases of diabetes, but the evidence is inconclusive. Objective: To evaluate whether the development of cancer is associated with increasing risk of subsequent diabetes. Design, Setting, and Participants: This cohort study included a nationally representative sample of the Korean general population observed for up to 10 years (January 1, 2003, to December 31, 2013). A total of 524 089 men and women 20 to 70 years of age without diabetes and with no history of cancer at baseline were included. Exposures: Incident cancer (time-varying exposure). Main Outcomes and Measures: Incident type 2 diabetes using insurance claim codes. Results: During 3 492 935.6 person-years of follow-up (median follow-up, 7.0 years) in 494 189 individuals (50.0% female; mean [SD] age, 41.8 [12.5] years), 15 130 participants developed cancer and 26 610 participants developed diabetes. After adjustment for age, sex, precancer diabetes risk factors, metabolic factors, and comorbidities, the hazard ratio (HR) for diabetes associated with cancer development was 1.35 (95% CI, 1.26-1.45; P < .001). The excess risk for diabetes was highest in the first 2 years after cancer diagnosis, but it remained elevated throughout follow-up. By cancer type, development of pancreatic (HR, 5.15; 95% CI, 3.32-7.99), kidney (HR, 2.06; 95% CI, 1.34-3.16), liver (HR, 1.95; 95% CI, 1.50-2.54), gallbladder (HR, 1.79; 95% CI, 1.08-2.98), lung (HR, 1.74; 95% CI, 1.34-2.24), blood (HR, 1.61; 95% CI, 1.07-2.43), breast (HR, 1.60; 95% CI, 1.27-2.01), stomach (HR, 1.35; 95% CI, 1.16-1.58), and thyroid cancer (HR, 1.33; 95% CI, 1.12-1.59) was associated with a significantly increased risk of diabetes. Conclusions and Relevance: In this large Korean cohort, cancer development increased the risk of subsequent diabetes. These data provide evidence that cancer is associated with an increased risk of diabetes in cancer survivors independent of traditional diabetes risk factors. Physicians should remember that patients with cancer develop other clinical problems, such as diabetes, with higher frequency than individuals without cancer, and should consider routine diabetes screening in these patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.